Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

PTC Therapeutics Swings to Q3 2026 Net Loss of $51.69 Million From Year-Earlier Profit

By Public Technologies
  • PTC Therapeutics swung to a third-quarter 2026 net loss of $51.69 million from year-earlier net income of $15.9 million.
  • Total revenue rose 70% year over year to $357.81 million, while product revenue more than doubled to $275.89 million.
  • Sephience revenue climbed 20% from the second quarter of 2026 to $181.9 million.
  • Newly acquired ST-920 Fabry disease therapy targets BLA submission completion in Q4 2026, with potential FDA accelerated approval in 2027.
  • Full-year 2026 revenue guidance increased to $1.29 billion–$1.32 billion, with product revenue projected at $960 million–$990 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610291601PR_NEWS_USPR_____NY85014) on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.